To include your compound in the COVID-19 Resource Center, submit it here.

Canakinumab reduces lung cancer mortality, headed for Phase III

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis. Spokesperson Eric Althoff told BioCentury that Novartis plans to start Phase III trials of the mAb against IL-1

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE